Leukaemia researcher, Professor Andrew Wei hopes that clinical trials in the future will be routinely based on a new strategy of targeting measurable residual disease (MRD), commencing patients on treatment before clinical relapse.
Professor Daniel Tenen, who has devoted his research career to searching for a cure for cancer, has found an “ideal target”. It’s a gene called SALL4.
This issue of preventable deaths is now being addressed along with other priority actions around national standards of care and consistent access to clinical best practice.
When talking to her patients, clinical haematologist and researcher Associate Professor Nada Hamad always considers their eligibility for a clinical trial.
A Phase I investigator-driven clinical trial, which is ready to recruit its first participant, gives Australian patients with high-risk MDS access to two new oral drugs.
Don Hayes had an allogeneic stem cell transplant days before his 71st birthday.
Research to further scientific knowledge of the cause and treatment of the uncommon type of blood cancer, Waldenström’s macroglobulinaemia (WM), is being co-funded by the Leukaemia Foundation.
More than 80% of children newly diagnosed with acute lymphoblastic leukaemia (ALL) are successfully treated today – an achievement deemed by Dr Michael Osborn as “one of the true success stories of modern medicine”.
